BODY & MIND INC.: directors' dealings · United States · SEC (Form 4)

About BODY & MIND INC.

Body and Mind Inc. (ticker BAMM) is a United States cannabis operator with investor communications aimed at North American capital markets. For the purpose of this brief, it should be viewed as a health-and-wellness adjacent equity within the broader U.S. listed universe, with investor attention often centered on insider activity disclosures and corporate events relevant to the NASDAQ/NYSE ecosystem. The company was originally formed as Deploy Technologies, then renamed Body and Mind Inc. after it completed the acquisition of Nevada Medical Group in November 2017. Since then, it has pursued a multi-state cannabis model combining cultivation, processing, and retail. Its operational footprint is associated with Las Vegas, Nevada, while its corporate history also includes Vancouver, underscoring its cross-border origins.\n\nBody and Mind builds and markets cannabis products under its BaM brand and, depending on local licenses and market conditions, operates dispensaries and production assets across selected U.S. states. Its product mix includes flower, pre-rolls, concentrates, vape cartridges, and edibles, with an emphasis on craft-oriented production, state-compliant testing, and brand consistency. The company is best described as a niche operator rather than a national scale leader. Its competitive position stems from operational know-how in limited-license jurisdictions, selective brand building, and a geographically diversified footprint rather than from sheer volume or market share dominance.\n\nGeographically, Body and Mind has historically maintained operations or projects in California, Nevada, Ohio, Arkansas, Michigan, as well as assets or initiatives linked to Illinois and New Jersey. This footprint reflects a state-by-state strategy aimed at capturing growth in regulated cannabis markets with different consumer profiles and licensing regimes. Recent developments have included continued portfolio optimization and asset transactions in 2025, including moves tied to dispensary and state-level operations. For French-speaking investors, BAMM is therefore a special-situations micro-cap cannabis name: attractive for its operating optionality, but also exposed to regulatory risk, local licensing constraints, balance-sheet sensitivity, and the liquidity profile typical of smaller U.S. listed names.